ZBIO
Zenas BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.79
+0.07%Year over year
Reported trailing growth
- Revenue
- -93.3%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +5567.5%
- EBITDA
- +37.7%
- EPS
- +49.3%
Three-year CAGR
- Revenue
- -55.3%
- EBITDA
- —
- EBIT
- -29.0%
- Net income
- —
- EPS
- —
- Free cash flow
- -43.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026